President Bill Clinton visited Cipla's factory in Goa today. Cipla produces antiretroviral (ARV) medicines and supplies many of the ARVs that are purchased through the Clinton Foundation's partnerships with governments in the developing world.
The Goa factory manufactures the pediatric ARV formulations that the Clinton Foundation has purchased as part of its program to jump-start pediatric treatment. President Clinton toured the factory with Cipla's Chairman Dr. Y.K. Hamied, and Joint Managing Director, Mr. Amar Lulla. He also met with a group of young pharmacists who are receiving training at Cipla's facility.
In November 2003, the Clinton Foundation announced agreements with Cipla and a number of other pharmaceutical companies that slashed the prices of antiretroviral medicines used to treat HIV/AIDS by more than 50% from lowest market rates. More recently, the Clinton Foundation and Cipla expanded their agreements to include efavirenz and abacavir as a first step to lower the cost of second line treatment. The prices for these drugs were reduced by more than 30% from current market rates. Cipla has also offered the Clinton Foundation pediatric formulation prices that were reduced by over 50% from market rates.
Speaking today President Clinton said, "Cipla's commitment to the expansion of care and treatment for people living with HIV/AIDS in the developing world is commendable. I am pleased to be here at Cipla's facilities, where so many of the AIDS drugs that are needed to keep people alive in the developing world are produced. I am grateful for our cooperation and thank Dr. Hamied, Mr. Lulla, and all of the Cipla team for their contribution to providing affordable antiretroviral drugs to the developing world."
Appearing with President Clinton, Mr. Lulla said "We are very happy to have President Clinton come to Cipla to further strengthen our relationship with the Clinton Foundation, and we look forward to working in more areas together."
# # #
Cipla was founded in 1935 by Dr. K.A. Hamied, the father of Cipla's chairman. Cipla is currently one of the leading pharmaceutical companies in India, with over 7,000 employees and 30 manufacturing facilities, and approvals from organizations and regulatory agencies such as the World Health Organization (WHO) and United States Food and Drug Administration (USFDA), among others. Cipla offers a range of 1300 products in 65 therapeutic areas.